<?xml version="1.0" encoding="UTF-8"?>
<p>Previous preclinical and clinical studies using the intramuscular route, in which MSC were administered as treatment for patients with critical limb ischaemia and/or non-healing ulcers, show that the treatment was well-tolerated and there was no evidence for local or systemic toxicity, as we discussed above.
 <xref rid="R17" ref-type="bibr">17 31 33 34</xref> Additionally, a number of clinical studies using cellular products for critical limb ischaemia in the upper limb have applied the intramuscular administration route with success.
 <xref rid="R57" ref-type="bibr">57â€“59</xref>
</p>
